![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2023
Bücklein, Veit; Perez, Ariel; Rejeski, Kai; Iacoboni, Gloria; Jurinovic, Vindi; Holtick, Udo; Penack, Olaf; Kharboutli, Soraya; Blumenberg, Viktoria; Ackermann, Josephine; Frölich, Lisa; Johnson, Grace; Patel, Kedar; Arciola, Brian; Mhaskar, Rahul; Wood, Anthony; Schmidt, Christian; Albanyan, Omar; Gödel, Philipp; Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Mackensen, Andreas; Locke, Frederick; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Barba, Pere; Subklewe, Marion und Jain, Michael D.
(2023):
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
In: HemaSphere, Bd. 7, Nr. 8, e907
ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Mackensen, Andreas; Locke, Frederick; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Barba, Pere; Subklewe, Marion und Jain, Michael D.
(2023):
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
In: HemaSphere, Bd. 7, Nr. 8, e907
2022
Rejeski, Kai ORCID: https://orcid.org/0000-0003-3905-0251; Perez, Ariel; Iacoboni, Gloria; Penack, Olaf; Bücklein, Veit; Jentzsch, Liv; Mougiakakos, Dimitrios; Johnson, Grace; Arciola, Brian; Carpio, Cecilia; Blumenberg, Viktoria; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Locke, Frederick L; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Mackensen, Andreas; Bethge, Wolfgang; Barba, Pere; Jain, Michael D ORCID: https://orcid.org/0000-0002-7789-1257 und Subklewe, Marion
(2022):
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
In: Journal for ImmunoTherapy of Cancer, Bd. 10, e004475
[PDF, 5MB]
ORCID: https://orcid.org/0000-0003-3905-0251; Perez, Ariel; Iacoboni, Gloria; Penack, Olaf; Bücklein, Veit; Jentzsch, Liv; Mougiakakos, Dimitrios; Johnson, Grace; Arciola, Brian; Carpio, Cecilia; Blumenberg, Viktoria; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Locke, Frederick L; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Mackensen, Andreas; Bethge, Wolfgang; Barba, Pere; Jain, Michael D ORCID: https://orcid.org/0000-0002-7789-1257 und Subklewe, Marion
(2022):
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
In: Journal for ImmunoTherapy of Cancer, Bd. 10, e004475
[PDF, 5MB]